Home | Welcome to Contract Pharma   
Last Updated Friday, October 31 2014
Print

Onyx Completes API Project



Published May 13, 2014
Onyx Scientific has completed a development and API manufacturing project to support Neuronascent’s pre-IND submission. Onyx provided process development and production of a 1kg batch of API along with supporting initial stability data for Neuronascent’s lead candidate NNI-362 for the potential treatment of Alzheimer’s and Parkinson’s disease and other neurodegenerative disorders. 
 
Onyx Scientific’s UK-based labs focus on challenging chemistry for early stage programs, along with scale-up and tech transfer using its commercial manufacturing sites in India.
 
Judith Kelleher-Andersson, Ph.D., founder, president and chief executive officer at Neuronascent said, “Onyx Scientific has the ability to synthesize high quality API, while still taking into account the time and financial concerns of a small biotech company.We have had a very positive experience in dealing with the entire Onyx Scientific team and they have played an important role in moving our Alzheimer’s disease project forward.” 
 
Denise Bowser, commercial director at Onyx Scientific, said, “We thoroughly enjoyed working with the team at Neuronascent and were able to deliver their project on time despite a pretty tight deadline.Early stage development and small scale manufacture of API has been our sweet spot for many years but we continue to improve to ensure we are meeting the needs of our clients across the world who are dealing with increased pressure to develop new products quicker than ever.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On